BacTech Schedules Special Meeting of Shareholders to Consider Plan of Arrangement

BacTech Mining Corporation ("BacTech" or the "Company") (TSX VENTURE:BM) today
announced that it has scheduled a special meeting of shareholders of BacTech to
be held on October 28, 2010, to consider and, if thought fit, approve a divisive
reorganization by way of a Plan of Arrangement. The record date for shareholders
entitled to receive notice of the meeting is September 27, 2010.


As previously announced, the Company is proposing to grant to a subsidiary
("BacTech Environmental") an exclusive, perpetual, royalty-free licence to use
BacTech's proprietary bioleaching technology for reclamation of historic mine
tailings. The Company will also assign to BacTech Environmental all of the
Company's rights and interest in existing and proposed tailings remediation
projects. The Company will retain the primary rights to the bioleaching
technology, as well as all of the Company's existing mining assets. 


Under the proposed Plan of Arrangement, BacTech shareholders will receive, in
exchange for each existing common share of the Company, one new common share of
the Company (which will be renamed REBgold Corporation) and one-fifth of a
common share of BacTech Environmental. 


Completion of the proposed reorganization is subject to receipt of all required
consents and approvals, including without limitation, court approval,
shareholder approval, and TSX Venture Exchange approval. 


The Company also announces that it will conduct a proposed private placement of
units of the Company for gross proceeds of up to $430,000 (the "Offering"). Each
unit will be comprised of a $10,000 unsecured convertible debenture, maturing on
the date that is 12 months following the closing of the Offering (the "Maturity
Date"), and 100,000 warrants. Each warrant shall entitle the holder to acquire
one common share of the Company at an exercise price of $0.12 until the Maturity
Date. 


The convertible debentures may be converted by the holders at any time at a
price of $0.10 per common share (the "Conversion Price"). In the event that the
closing price of the Company's common shares on the TSXV is at or greater than
$0.15, the Company shall have the right, in its sole discretion, to redeem the
convertible debentures through the issuance of common shares at the Conversion
Price. The interest rate on the convertible debentures will be 1.5% per month,
which shall be paid semi-annually. The private placement is subject to requisite
regulatory approval, including the approval of the TSX Venture Exchange. Certain
of the debentures are being issued to replace previous debentures that have
since matured. The remainder of the proceeds will be used for ongoing project
evaluation and working capital.


BACTECH PROFILE

BacTech owns patented bacterial oxidation technology for the treatment of
refractory ores and concentrates to enhance the recovery of gold, silver and
base metals. The Company's initial focus is the acquisition of equity positions
in projects amenable to bioleaching.


Shares outstanding 132,943,039